High Efficacy of Fractionated Stereotactic Radiotherapy of Large Base-of-Skull Meningiomas: Long-Term Results

Debus, Jürgen; Wuendrich, Martina; Pirzkall, Andrea; Hoess, Angelika; Schlegel, Wolfgang; Zuna, I.; Engenhart‐Cabillic, Rita; Wannenmacher, M.

doi:10.1200/jco.2001.19.15.3547

Cited by 263 publications

(132 citation statements)

References 25 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Recently, 5-and 10-year actuarial overall survival rates of 97% and 96% at a mean follow-up of 35 months for 189 patients with World Health Organization (WHO) grade I and II meningiomas treated with FSRT were reported by the Heidelberg group. 44 Local failure was observed in three of 180 patients with WHO grade I tumors and two of nine patients with WHO grade II tumors. Clinically significant treatment-related toxicity was observed in 1.6% of the patients.…”

Section: Stereotactic Radiotherapymentioning

confidence: 98%

Single Dose versus Fractionated Stereotactic Radiotherapy for Meningiomas

Cho

Hall

et al. 2002

Can. j. neurol. sci.

View full text Add to dashboard Cite

240Meningiomas constitute approximately 20% of all primary intracranial tumors.1,2 Tumor grade rather than histologic subtype bears clear prognostic importance. [3][4][5][6][7][8][9] Complete surgical excision, if achievable, can produce excellent results without adjunctive therapy. [9][10][11] However, meningiomas may recur after surgery and curative resection can result in significant morbidity because of strategic tumor location and old age. [12][13][14][15] Stereotactic radiosurgery (SRS) can deliver a single high dose of radiation to a localized area in the brain for the treatment of meningiomas that are unresectable, recurrent or residual after surgery. However, large tumors and tumors adjacent to vital ABSTRACT: Objective: To evaluate the safety and efficacy of stereotactic radiosurgery (SRS) compared to fractionated stereotactic radiation therapy (FSRT) for meningiomas treated over a seven year period. Methods and materials: Of the 53 patients (15 male and 38 female) with 63 meningiomas, 35 were treated with SRS and the 18 patients with tumors adjacent to critical structures or with large tumors were treated with FSRT. The median doses for the SRS and the FSRT groups were 1400 cGy (500-4500 cGy) and 5400 cGy (4000-6000 cGy) respectively. Median target volumes for SRS and FSRT were 6.8 ml and 8.8 ml respectively. The median follow-up for the SRS and FSRT groups were 38 months (4.1-97 months) and 30.5 months (6.0-63 months) respectively. Results: The five-year tumor control probability (TC) for benign versus atypical meningiomas were 92.7% vs. 31% (P=.006). The three-year TC were 92.7% vs. 93.3% for SRS vs. FSRT groups respectively (P=.62). For benign meningiomas, the three-year TC were 92.9% vs. 92.3% for the SRS group (29 patients) vs. FSRT group (14 patients) respectively (P=.77). Two patients in the SRS group and one in the FSRT group developed late complications. Conclusion: Preliminary data suggest that SRS is a safe and effective treatment for patients with benign meningiomas. Fractionated stereotactic radiation therapy with conventional fractionation appeared to be an effective and safe treatment alternative for patients not appropriate for SRS. A longer follow-up is required to determine the long-term efficacy and the toxicity of these treatment modalities.RÉSUMÉ: Dose unique versus radiothérapie stéréotaxique fractionnée dans le traitement des méningiomes. Objectif: Évaluer la sécurité et l'efficacité de la radiochirurgie stéréotaxique (RCS) comparée à la radiothérapie stétéotaxique fractionnée (RTSF) dans le traitement des méningiomes sur une période de sept ans. Méthodes et matériels: Parmi les 53 patients (15 hommes et 38 femmes) atteints de 63 méningiomes, 35 ont été traités par RCS et 18, dont la tumeur était adjacente à des structures critiques ou était volumineuse, ont été traités par RTSF. Les doses médianes pour le groupe RCS et le groupe RTSF étaient de 1400 cGy (500 à 4500 cGy) et 5400 cGy (4000 à 6000 cGy) respectivement. Les volumes cibles médians pour les groupes RCS et RTSF étaient...

show abstract

Section: Stereotactic Radiotherapymentioning

confidence: 98%

Single Dose versus Fractionated Stereotactic Radiotherapy for Meningiomas

Cho

Hall

et al. 2002

Can. j. neurol. sci.

View full text Add to dashboard Cite

show abstract

“…Excellent tumor control (90-100%) and preservation of cranial nerve function has been reported with daily radiation of 1.8-2.0 Gy per fraction to doses of 50-60 Gy over 5-7 weeks [18,19,[41][42][43][44][45][46][47][48][49].…”

Section: Hypofractionatedmentioning

confidence: 99%

Clinical outcome after Hypofractionated Stereotactic Radiotherapy (HSRT) for benign skull base tumors

Mahadevan¹,

Floyd²,

Wong

et al. 2011

Computer Aided Surgery

View full text Add to dashboard Cite

“…Em pacientes que receberam baixas doses (<10 Gy) é, em média 35,2 anos e 18,7 anos naqueles que receberam altas doses (>20 Gy) 7 . Mack e Wilson observaram um período de latência de 27 anos para doses moderadas (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20) 19 . Estes diferentes períodos de latência sugerem que o maior dano ao cromossomo causado por doses maiores de radiação induz à perda mais rápida do mecanismo de controle celular e à expressão fenotípica neoplásica mais precoce 7 .…”

Section: Discussionunclassified

Meningeoma pós-radioterapia

Barboza¹,

Panagopoulos²,

Lancellotti³

et al. 2006

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Os meningeomas são neoplasias derivadas das células aracnóideas, sendo sua origem ligada a alterações genéticas idiopáticas (deleção do braço longo do cromossomo 22), doenças predisponentes à sua formação e indução por radioterapia. Relata-se o caso de um homem de 50 anos com meningeoma pós-radioterapia diagnosticado 20 anos após o tratamento de um oligodendroglioma. Os critérios que suportam o diagnóstico de meningeoma induzido por radioterapia são discutidos, assim como é revisada a literatura pertinente ao assunto.

show abstract

High Efficacy of Fractionated Stereotactic Radiotherapy of Large Base-of-Skull Meningiomas: Long-Term Results

Abstract: The results of this study demonstrate that fractionated stereotactic radiotherapy is safe and effective in the therapy of subtotally resected or unresectable meningiomas. The overall morbidity and incidence subacute and late side effects of this conformal radiotherapy approach were low.

Cited by 263 publications

References 25 publications

Single Dose versus Fractionated Stereotactic Radiotherapy for Meningiomas

Single Dose versus Fractionated Stereotactic Radiotherapy for Meningiomas

Clinical outcome after Hypofractionated Stereotactic Radiotherapy (HSRT) for benign skull base tumors

Meningeoma pós-radioterapia

Contact Info

Product

Resources

About